Filtered By:
Vaccination: Cancer Vaccines

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 1080 results found since Jan 2013.

Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies
CONCLUSION: Immune responses were impaired in individuals with hematologic malignancies, particularly patients undergoing ongoing therapy and B-cell-depleting therapy. Additional vaccinations should be considered for these patients, and further investigated.PMID:37214149 | PMC:PMC10193112 | DOI:10.7774/cevr.2023.12.2.107
Source: Cell Research - May 22, 2023 Category: Cytology Authors: Chayapa Thookhamme Manassamon Navinpipat Aimwipa Sasakul Pakthipa Pattarakosol Kamoltip Lertchaisataporn Kriangkrai Tawinprai Pannee Praditsuktavorn Source Type: research

Outcomes of cancer patients with COVID-19: the Virginia Commonwealth University experience
CONCLUSION: The mortality rate of cancer patients was 10.5%, lower than other studies. Vaccinations had mortality benefit, but no effect on hypoxia, ventilator use, or LOS. Delaying cancer therapy during peak infection is likely not necessary based on results of this study. With improved knowledge in the risks of infection and utility of personalized precautions, both providers and patients can better prepare for another potential wave of COVID-19.PMID:37194996 | DOI:10.1080/07357907.2023.2215325
Source: Cancer Investigation - May 17, 2023 Category: Cancer & Oncology Authors: Patrick J Willard Yiwei Hang Temitayo Olasehinde Naji Bou Zeid Edem Defor Dipankar Bandyopadhyay Victor Yazbeck Source Type: research

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2
MedComm (2020). 2023 May 14;4(3):e254. doi: 10.1002/mco2.254. eCollection 2023 Jun.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic has affected a large portion of the global population, both physically and mentally. Current evidence suggests that the rapidly evolving coronavirus subvariants risk rendering vaccines and antibodies ineffective due to their potential to evade existing immunity, with enhanced transmission activity and higher reinfection rates that could lead to new outbreaks across the globe. The goal of viral management is to disrupt the viral life cycle as well as to relieve severe symptoms such as l...
Source: Cancer Control - May 16, 2023 Category: Cancer & Oncology Authors: Yiying Xue Husheng Mei Yisa Chen James D Griffin Qingsong Liu Ellen Weisberg Jing Yang Source Type: research

SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice
This study evaluated the booster effect of an S1 subunit vaccine in aged mice that had been previously primed with adenoviral vaccines, providing valuable preclinical evidence for elderly people vaccinated with the currently approved COVID-19 vaccines. This study confirms the potential for using the S1 subunit vaccine as a booster to enhance cross-neutralizing antibodies against emerging variants of concern.PMID:37162333 | DOI:10.1128/spectrum.04363-22
Source: Cancer Control - May 10, 2023 Category: Cancer & Oncology Authors: Eun Kim Muhammad S Khan Alessandro Ferrari Shaohua Huang Jos è C Sammartino Elena Percivalle Thomas W Kenniston Irene Cassaniti Fausto Baldanti Andrea Gambotto Source Type: research

Insights from establishing a high throughput viral diagnostic laboratory for SARS-CoV-2 RT-PCR testing facility: challenges and experiences
Front Public Health. 2023 Apr 17;11:1122715. doi: 10.3389/fpubh.2023.1122715. eCollection 2023.ABSTRACTBackground: The World Health Organization declared the coronavirus disease 2019 (COVID-19) a global pandemic on 11 March 2020. Identifying the infected people and isolating them was the only measure that was available to control the viral spread, as there were no standardized treatment interventions available. Various public health measures, including vaccination, have been implemented to control the spread of the virus worldwide. India, being a densely populated country, required laboratories in different zones of the co...
Source: Cancer Control - May 5, 2023 Category: Cancer & Oncology Authors: Sanchita Roy Pradhan M H Yashavarddhan Ashish Gupta Pramod Kumar Anuj Kumar Nazneen Arif Usha Agrawal R Suresh Kumar Shalini Singh Source Type: research

COVID-19 Dropped to 4th Leading Cause of Death in U.S. Last Year
NEW YORK — U.S. deaths fell last year, and COVID-19 dropped to the nation’s No. 4 cause, the Centers for Disease Control and Prevention reported Thursday. COVID-19 deaths trailed those caused by heart disease, cancer and injuries such as drug overdoses, motor vehicle fatalities, and shootings. In 2020 and 2021, only heart disease and cancer were ahead of the coronavirus. U.S. deaths usually rise year-to-year, in part because the nation’s population has been growing. The pandemic accelerated that trend, making 2021 the deadliest in U.S. history, with more than 3.4 million deaths. But 2022 saw the first dro...
Source: TIME: Health - May 4, 2023 Category: Consumer Health News Authors: Mike Stobbe/AP Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news

Letter re: SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis
We read the article by Giugliano et al.  [1] entitled 'SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: brief report of a TYME network safety analysis,' published in the European Journal of Cancer, with great interest. The authors suggested that SARS-CoV-2 mRNA vaccines were safe in patients with thymic epithelial tumours, even in those with active or pre-existing autoimmune disorders; however, the safety of coronavirus disease 2019 (COVID-19) vaccination in such patients should be further discussed and evaluated.
Source: European Journal of Cancer - April 30, 2023 Category: Cancer & Oncology Authors: Atsunori Baba, Takuya Tokunaga, Koichi Sakasegawa, Takuro Kanekura, Hirohito Tsubouchi Tags: Letter to the Editor Source Type: research

Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia
ConclusionsThis study highlighted the significance of booster SARS-CoV-2 mRNA vaccination in patients with PCD with respect to humoral and cellular immunity. Moreover, this study highlighted the potential impact of certain drug subclasses on vaccine-induced humoral immune response.
Source: Cancer Medicine - April 27, 2023 Category: Cancer & Oncology Authors: Tomotaka Suzuki, Shigeru Kusumoto, Yoshiko Kamezaki, Hiroya Hashimoto, Nozomi Nishitarumizu, Yoko Nakanishi, Yukiyasu Kato, Akimi Kawai, Naohiro Matsunaga, Toru Ebina, Tomoyuki Nakamura, Yoshiaki Marumo, Kana Oiwa, Shiori Kinoshita, Tomoko N Tags: RESEARCH ARTICLE Source Type: research